🇺🇸·3h agoIndustry
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Publisher
M
Merck & Co. (MSD) News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Merck & Co. (MSD) News
- Region
- USA
- Scope
- Industry
- Published
- June 22, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on merck.com
Leave the platform to read the original full article on the publisher site.
Source: Merck & Co. (MSD) News
Scope: Industry
Related coverage
More related coverage
AbbVie News/2h ago
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
Laboratorios Rovi/4h ago
La adquisición de ROIS PHOENIX marca un nuevo hito en la internacionalización del negocio de fabricación a terceros de ROIS
Laboratorios Rovi/5h ago
Acuerdos aprobados y votaciones
BioSpace Newsroom/9h ago